Marc Stapley Sells 15,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) Director Marc Stapley sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the sale, the director directly owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This trade represents a 28.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Glaukos Stock Performance

NYSE GKOS opened at $118.75 on Wednesday. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $161.78. The company has a market cap of $6.82 billion, a P/E ratio of -77.11 and a beta of 0.67. The company has a fifty day simple moving average of $111.79 and a 200 day simple moving average of $96.40. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same quarter last year, the company earned ($0.28) earnings per share. The company’s revenue for the quarter was up 38.1% on a year-over-year basis. Sell-side analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on GKOS shares. UBS Group lifted their target price on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Truist Financial raised their price target on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Citigroup boosted their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Wells Fargo & Company increased their price objective on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Finally, Stifel Nicolaus increased their target price on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $131.38.

Institutional Investors Weigh In On Glaukos

A number of institutional investors have recently modified their holdings of GKOS. Norges Bank bought a new position in Glaukos during the second quarter valued at approximately $76,314,000. Primecap Management Co. CA boosted its position in shares of Glaukos by 50.0% in the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after purchasing an additional 609,523 shares during the period. Alliancebernstein L.P. raised its holdings in Glaukos by 38.5% during the third quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock valued at $141,365,000 after acquiring an additional 481,620 shares during the period. AustralianSuper Pty Ltd bought a new stake in Glaukos during the 2nd quarter valued at approximately $41,946,000. Finally, William Blair Investment Management LLC lifted its holdings in shares of Glaukos by 52.4% in the second quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock worth $117,347,000 after buying an additional 390,805 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.